Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 16, 2025Journal of Advanced ResearchOpen Access

The eternal struggle between titans: Fecal microbiota transplant (FMT) versus metformin in type 2 diabetes (T2D) gut dysmotility

View Full Paper
Ask AI
Bookmark
Share

Authors

LSLucia La SalaVCValentina CarliniMMMaria Belen Macas-Granizo

Discussion

Loading...

Member takes

Overview

This review evaluates fecal microbiota transplant and metformin in type 2 diabetes, highlighting their effects on dysbiosis and gut motility.

Key Points

  • Fecal microbiota transplant may improve insulin sensitivity and glucose tolerance in type 2 diabetes.
  • Metformin shows efficacy in managing metabolic parameters but can trigger gastrointestinal side effects.
  • Understanding the mechanisms behind fecal microbiota transplant and metformin offers insights into gut dysmotility issues.
  • The potential integration of these therapies warrants further research into their safety profiles and effectiveness.

Cite This Study

Sala et al. (2025) studied this question.

synapsesocial.com/papers/68d42321713b0b5dfea6ae05https://doi.org/10.1016/j.jare.2025.09.021
View Full Paper
Ask AI
Bookmark
Share